Life Sciences Tools and Services
Company Overview of 10X Genomics, Inc.
10X Genomics, Inc. develops integrated systems and solutions for genome sequencing, exome sequencing, and single cell transcriptomics. The company offers Chromium Single Cell 3' Kit that enables the discovery of gene expression dynamics for profiling individual cell types with single cell expression measurements; Chromium Genome that provides long range information on a genome-wide scale, including variant calling, phasing, and extensive characterization of genomic structure; and Chromium Exome that enables to resolve genic phasing, structural variation, and detect variants in previously inaccessible and complex regions. Its Chromium Single Cell 3' Kit comprises reagents to enable sample par...
7068 Koll Center Parkway
Pleasanton, CA 94566
Founded in 2012
Key Executives for 10X Genomics, Inc.
Co-Founder, Chief Executive Officer and Director
Co-Founder, President, Chief Scientific Officer and Director
Vice President of Finance
Senior Vice President of Global Sales and Commercial Operations
Compensation as of Fiscal Year 2016.
10X Genomics, Inc. Key Developments
10x Genomics Launches Comprehensive Software Suite for Single-Cell RNA-seq Data Analysis and Visualization
Feb 13 17
10x Genomics announced the launch of a new software suite for analyzing and visualizing single-cell RNA sequencing (scRNA-seq) data generated by the company’s Chromium™ Single Cell 3’ Solution. The new software suite, announced at the 17th Annual Advances in Genome Biology and Technology (AGBT) Meeting, includes the Loupe™ Cell Browser and an updated version of Cell Ranger™ pipelines, which together provide a complete and seamless analysis workflow for detailed gene expression profiling information on a cell-by-cell basis. The Loupe Cell Browser is an easy-to-use, interactive visualization tool that delivers insights into single-cell gene expression. With the Loupe Cell Browser, researchers can easily identify distinct cellular sub-populations, isolate significant genes, measure expression levels, and export findings for further analysis and collaborative sharing. The updated Cell Ranger, a set of analysis pipelines that combine robust transcriptome alignment with cellular barcoding to rapidly generate expression profiles across tens of thousands of cells at once, now automatically generates Loupe Cell Browser-ready files for both single-sample and multi-sample experiments. Cell Ranger pipelines also feature a powerful new graph-based clustering method with the ability to identify and resolve more cellular sub-populations within single-cell experiments. The new release also increases transcriptome mapping rate and optimizes computational performance to enable the analysis of large-scale datasets of over one million cells.
10X Genomics, Inc. Appoints Bradford J. Crutchfield as Chief Commercial Officer
Feb 9 17
10x Genomics announced the appointment of Bradford J. Crutchfield as chief commercial officer of the company. Mr. Crutchfield will oversee global sales, marketing, business development and customer support. John Pouk, the company’s interim chief commercial officer, will work closely with Mr. Crutchfield in his new role as senior vice president of commercial operations. Mr. Crutchfield brings more than 30 years of experience in commercial sales and marketing leadership to the company. Prior to joining 10x Genomics, Mr. Crutchfield served as QIAGEN’s senior vice president, life sciences business area, expanding their presence in the academic, pharmaceutical and applied testing industries. Prior, he served as vice president and general manager, Europe, Middle East & Africa, for Illumina. From 1985 to 2014, Mr. Crutchfield held positions of increasing responsibility with Bio-Rad Laboratories Inc., rising to executive vice president and president of the Life Science Group. In 2013 and 2014 he was a director of NanoString Technologies, Inc.
10x Genomics, Inc. Announces Publication of Study in Nature Communications Demonstrating Single Cell Profiling in Leukemia Patients by the Fred Hutchinson Cancer Research Center
Jan 16 17
10x Genomics, Inc. announced the publication of a study enabled by the company’s Chromium™ Single Cell 3’ Solution. This new technology provides robust single-cell expression measurements, allowing the discovery of gene expression dynamics and molecular profiling of individual cell types at scale. To demonstrate the technical performance and applications of the Chromium Single Cell 3’ Solution, the researchers collected transcriptome data from approximately 250,000 single cells across 29 samples. Results showed superior scalability and robustness of this system for single cell RNA-sequencing, with comparable sensitivity to existing methods. The system’s rapid cell encapsulation and high cell capture efficiency enabled analysis of precious clinical samples from patients with acute myeloid leukemia. Using the Chromium Single Cell 3’ Solution, researchers determined host and donor chimerism at single cell resolution and compared immune cell subpopulation changes in patients before and after transplant. Existing methods for single-cell RNA-sequencing face practical challenges when scaling to tens of thousands or more cells in throughput. The commercially available Chromium Single Cell 3’ Solution enables single cell RNA-sequencing at scale, with high cell capture efficiency and flexible throughput. Current plate-based approaches require time-consuming fluorescence-activated cell sorting (FACS) into many plates that must be processed separately. Microfluidics-based platforms utilize mechanical trapping of cells and are limited in their throughput and cell capture efficiency. Academic droplet-based techniques enable processing of tens of thousands of cells in a single experiment but are not efficient to implement, or robustly scale. The published data demonstrates the Chromium Single Cell 3’ Solution can address both of these shortcomings in a single assay, resulting in a more scalable and robust platform for single cell RNA-sequencing.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|